Cargando…

Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients

OBJECTIVE: To evaluate the efficacy of degludec/aspart (IDegAsp) insulin co-formulation in children and adolescents with poorly controlled type 1 diabetes (T1DM). METHODS: Patients with poorly controlled T1DM on basal-bolus insulin regimes and having compliance problems related to insulin injections...

Descripción completa

Detalles Bibliográficos
Autores principales: Kırkgöz, Tarık, Eltan, Mehmet, Kaygusuz, Sare Betül, Yavaş Abalı, Zehra, Helvacıoğlu, Didem, Seven Menevşe, Tuba, Gürpınar Tosun, Büşra, Güran, Tülay, Bereket, Abdullah, Turan, Serap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900081/
https://www.ncbi.nlm.nih.gov/pubmed/34355879
http://dx.doi.org/10.4274/jcrpe.galenos.2021.2021.0113
_version_ 1784664034478391296
author Kırkgöz, Tarık
Eltan, Mehmet
Kaygusuz, Sare Betül
Yavaş Abalı, Zehra
Helvacıoğlu, Didem
Seven Menevşe, Tuba
Gürpınar Tosun, Büşra
Güran, Tülay
Bereket, Abdullah
Turan, Serap
author_facet Kırkgöz, Tarık
Eltan, Mehmet
Kaygusuz, Sare Betül
Yavaş Abalı, Zehra
Helvacıoğlu, Didem
Seven Menevşe, Tuba
Gürpınar Tosun, Büşra
Güran, Tülay
Bereket, Abdullah
Turan, Serap
author_sort Kırkgöz, Tarık
collection PubMed
description OBJECTIVE: To evaluate the efficacy of degludec/aspart (IDegAsp) insulin co-formulation in children and adolescents with poorly controlled type 1 diabetes (T1DM). METHODS: Patients with poorly controlled T1DM on basal-bolus insulin regimes and having compliance problems related to insulin injections were switched to IDegAsp and were included. Data on hemoglobin A1c (HbA1c) levels, hypoglycemic episodes, frequency of diabetic ketoacidosis (DKA) and insulin doses were recorded at baseline and after one year of IDegAsp treatment. RESULTS: Fifty patients (22 girls; 44%) were started on IDegAsp. The mean±standard deviation (range) age and duration of diabetes were 12.9±3.4 (4-18) and 5.2±3.1 (1.0-13.7) years, respectively. At the end of one year, 38 patients were still on IDegAsp, whereas 12 patients had opted to resume their original treatments. In those who continued on IDegAsp, HbA1c levels did not change, but the number of self-reported mild-moderate hypoglycemic episodes decreased significantly (p<0.05). In the year before switching to IDegAsp, 11 DKA attacks in 9 patients were observed, whereas this decreased to 4 DKA attacks in 4 patients after one year of IDegAsp therapy (p=0.06). CONCLUSION: IDegAsp regimen may improve clinical management in poorly controlled basal-bolus insulin regimen T1DM patients who have frequent hypoglycemia and DKA attacks, as well as in those with poor compliance with multiple injections. Although a simplified basal-bolus IDegAsp regimen is an attractive option for patients with T1DM, some may not adapt to this treatment due to the fixed IAsp dose of IDegAsp.
format Online
Article
Text
id pubmed-8900081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-89000812022-03-17 Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients Kırkgöz, Tarık Eltan, Mehmet Kaygusuz, Sare Betül Yavaş Abalı, Zehra Helvacıoğlu, Didem Seven Menevşe, Tuba Gürpınar Tosun, Büşra Güran, Tülay Bereket, Abdullah Turan, Serap J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: To evaluate the efficacy of degludec/aspart (IDegAsp) insulin co-formulation in children and adolescents with poorly controlled type 1 diabetes (T1DM). METHODS: Patients with poorly controlled T1DM on basal-bolus insulin regimes and having compliance problems related to insulin injections were switched to IDegAsp and were included. Data on hemoglobin A1c (HbA1c) levels, hypoglycemic episodes, frequency of diabetic ketoacidosis (DKA) and insulin doses were recorded at baseline and after one year of IDegAsp treatment. RESULTS: Fifty patients (22 girls; 44%) were started on IDegAsp. The mean±standard deviation (range) age and duration of diabetes were 12.9±3.4 (4-18) and 5.2±3.1 (1.0-13.7) years, respectively. At the end of one year, 38 patients were still on IDegAsp, whereas 12 patients had opted to resume their original treatments. In those who continued on IDegAsp, HbA1c levels did not change, but the number of self-reported mild-moderate hypoglycemic episodes decreased significantly (p<0.05). In the year before switching to IDegAsp, 11 DKA attacks in 9 patients were observed, whereas this decreased to 4 DKA attacks in 4 patients after one year of IDegAsp therapy (p=0.06). CONCLUSION: IDegAsp regimen may improve clinical management in poorly controlled basal-bolus insulin regimen T1DM patients who have frequent hypoglycemia and DKA attacks, as well as in those with poor compliance with multiple injections. Although a simplified basal-bolus IDegAsp regimen is an attractive option for patients with T1DM, some may not adapt to this treatment due to the fixed IAsp dose of IDegAsp. Galenos Publishing 2022-03 2022-03-03 /pmc/articles/PMC8900081/ /pubmed/34355879 http://dx.doi.org/10.4274/jcrpe.galenos.2021.2021.0113 Text en ©Copyright 2022 by Turkish Pediatric Endocrinology and Diabetes Society | The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kırkgöz, Tarık
Eltan, Mehmet
Kaygusuz, Sare Betül
Yavaş Abalı, Zehra
Helvacıoğlu, Didem
Seven Menevşe, Tuba
Gürpınar Tosun, Büşra
Güran, Tülay
Bereket, Abdullah
Turan, Serap
Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title_full Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title_fullStr Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title_full_unstemmed Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title_short Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
title_sort efficacy of the novel degludec/aspart insulin co-formulation in children and adolescents with type 1 diabetes: a real-life experience with one year of idegasp therapy in poorly controlled and non-compliant patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900081/
https://www.ncbi.nlm.nih.gov/pubmed/34355879
http://dx.doi.org/10.4274/jcrpe.galenos.2021.2021.0113
work_keys_str_mv AT kırkgoztarık efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT eltanmehmet efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT kaygusuzsarebetul efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT yavasabalızehra efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT helvacıogludidem efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT sevenmenevsetuba efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT gurpınartosunbusra efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT gurantulay efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT bereketabdullah efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients
AT turanserap efficacyofthenoveldegludecaspartinsulincoformulationinchildrenandadolescentswithtype1diabetesareallifeexperiencewithoneyearofidegasptherapyinpoorlycontrolledandnoncompliantpatients